Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Fiche publication
Date publication
décembre 2020
Journal
The Lancet. Haematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DORVAUX Véronique
Tous les auteurs :
Roussel M, Moreau P, Hebraud B, Laribi K, Jaccard A, Dib M, Slama B, Dorvaux V, Royer B, Frenzel L, Zweegman S, Klein SK, Broijl A, Jie KS, Wang J, Vanquickelberghe V, de Boer C, Kampfenkel T, Gries KS, Fastenau J, Sonneveld P
Lien Pubmed
Résumé
In part 1 of the two-part CASSIOPEIA study, treatment before and after autologous haematopoietic stem-cell transplantation (HSCT) with daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) significantly improved rates of stringent complete response and progression-free survival versus bortezomib, thalidomide, and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma.
Mots clés
Antibodies, Monoclonal, pharmacology, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, pharmacology, Dexamethasone, pharmacology, Female, Humans, Male, Multiple Myeloma, drug therapy, Quality of Life, psychology, Thalidomide, pharmacology
Référence
Lancet Haematol. 2020 12;7(12):e874-e883